Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-B... von Hickish, Tamas, Mehta, Ajay, Liu, Mei-Ching, Huang, Chiun-Sheng, Arora, Rajendra Singh, Chang, Yuan-Ching, Yang, Youngsen, Vladimirov, Vladimir, Jain, Minish, Tsang, Janice, Pemberton, Karine, Sadrolhefazi, Behbood, Jin, Xidong, Tseng, Ling-Ming

Volltext

Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours von Schoffski, Patrick, Machiels, Jean-Pascal, Rottey, Sylvie, Sadrolhefazi, Behbood, Musa, Hanny, Marzin, Kristell, Awada, Ahmad

Volltext

A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations von Heymach, John, Opdam, Frans, Barve, Minal A., Gibson, Neil, Sadrolhefazi, Behbood, Serra, Josep, Yamamoto, Noboru

Volltext

A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations von Heymach, John, Opdam, Frans, Barve, Minal, Gibson, Neil, Sadrolhefazi, Behbood, Serra, Josep, Yamamoto, Noboru

Volltext

Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours von Schöffski, Patrick, Machiels, Jean-Pascal, Rottey, Sylvie, Sadrolhefazi, Behbood, Musa, Hanny, Marzin, Kristell, Awada, Ahmad

Volltext

Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Up... von Heymach, John, Opdam, Frans, Barve, Minal A., Tu, Hai-Yan, Wu, Yi-Long, Berz, David, Gibson, Neil, Sadrolhefazi, Behbood, Serra, Josep, Yoh, Kiyotaka, Yamamoto, Noboru

Volltext

OA01.01 Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors von Heymach, John, Yamamoto, Noboru, Opdam, Frans, Barve, Minal, Tu, Hai-Yan, Wu, Yi-Long, Schroeter, Lukas, Sadrolhefazi, Behbood, Serra, Josep, Yoh, Kiyotaka, Berz, David

Volltext

Abstract CT212: A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER... von Heymach, John, Opdam, Frans, Barve, Minal, Gibson, Neil, Sadrolhefazi, Behbood, Serra, Josep, Yamamoto, Noboru

Volltext

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer von Martin, Nicolas, Isambert, Nicolas, Gomez-Roca, Carlos, Goeldner, Rainer-Georg, Zanetta, Sylvie, Sadrolhefazi, Behbood, de Mont-Serrat, Hélène, Campone, Mario, Delord, Jean-Pierre

Volltext

A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment... von Ellis, Peter M, Leighl, Natasha B, Hirsh, Vera, Reaume, M. Neil, Blais, Normand, Wierzbicki, Rafal, Sadrolhefazi, Behbood, Gu, Yu, Liu, Dan, Pilz, Korinna, Chu, Quincy

Volltext

Abstract CT203: Updated data from the Phase I Beamion Lung 1 trial of the HER2 tyrosine kinase inhibitor (TKI), BI 1810631, as monotherapy in patients (pts) with advanced/metastati... von Heymach, John, Opdam, Frans, Barve, Minal, Tu, Hai-Yan, Wu, Yi-Long, Gibson, Neil, Sadrolhefazi, Behbood, Serra, Josep, Yoh, Kiyotaka, Yamamoto, Noboru

Volltext

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol von Levy, Benjamin, Paz-Ares, Luis, Bennouna, Jaafar, Felip, Enriqueta, Abreu, Delvys Rodríguez, Isla, Dolores, Barlesi, Fabrice, Molinier, Olivier, Madelaine, Jeannick, Audigier-Valette, Clarisse, Kim, Sang-We, Kim, Hye Ryun, Ozguroglu, Mustafa, Erman, Mustafa, Badin, Firas Benyamine, Mekhail, Tarek M., Scheff, Ronald, Chisamore, Michael J., Sadrolhefazi, Behbood, Riess, Jonathan W.

Volltext

High Prevalence of HER-2/neu Overexpression among Iranian Women with Breast Cancer: True or False? von Saatee, Siavosh, Afrakhteh, Maryam, Sadrolhefazi, Behbood

Volltext

DOSING SCHEDULE OF A HER2 INHIBITOR von CHYLINSKI, Krzysztof, SCHROETER, Lukas, SERRA, Josep, WIND, Sven, VON WANGENHEIM, Ute, BAUM, Anke, GIBSON, Neil, SCHARN, Dirk, NEUMUELLER, Ralph, SADROLHEFAZI, Behbood

Volltext bestellen

DOSING SCHEDULE OF A SOLID DISPERSION OF A HER2 INHIBITOR von SMITHEY, Daniel Tod, SCHROETER, Lukas, SCHLESINGER, Erica B, VON WANGENHEIM, Ute, BAUM, Anke, SCHARN, Dirk, CHEN, Shirlynn, NEUMUELLER, Ralph, LOTZ, Ralf Richard Hermann, WALD, Randy Joseph, SERRA, Josep, WIND, Sven, GIBSON, Neil, SADROLHEFAZI, Behbood

Volltext bestellen